Identification of TRIM25 as a Negative Regulator of Caspase-2 Expression Reveals a Novel Target for Sensitizing Colon Carcinoma Cells to Intrinsic Apoptosis

Cells. 2019 Dec 12;8(12):1622. doi: 10.3390/cells8121622.

Abstract

Colorectal cancer (CRC) is one of the most common cancers that is characterized by a high mortality due to the strong metastatic potential of the primary tumor and the high rate of therapy resistance. Hereby, evasion of apoptosis is the primary underlying cause of reduced sensitivity of tumor cells to chemo- and radiotherapy. Using RNA affinity chromatography, we identified the tripartite motif-containing protein 25 (TRIM25) as a bona fide caspase-2 mRNA-binding protein in colon carcinoma cells. Loss-of-function and gain-of-function approaches revealed that TRIM25 attenuates the protein levels of caspase-2 without significantly affecting caspase-2 mRNA levels. In addition, experiments with cycloheximide revealed that TRIM25 does not affect the protein stability of caspase-2. Furthermore, silencing of TRIM25 induced a significant redistribution of caspase-2 transcripts from RNP particles to translational active polysomes, indicating that TRIM25 negatively interferes with caspase-2 translation. Functionally, the elevation in caspase-2 upon TRIM25 depletion significantly increased the sensitivity of colorectal cells to drug-induced intrinsic apoptosis as implicated by increased caspase-3 cleavage and cytochrome c release. Importantly, the apoptosis-sensitizing effects by transient TRIM25 knockdown were rescued by concomitant silencing of caspase-2, demonstrating a critical role of caspase-2. Inhibition of caspase-2 by TRIM25 implies a survival mechanism that critically contributes to chemotherapeutic drug resistance in CRC.

Keywords: TRIM25; caspase-2; chemotherapy resistance; colon carcinoma cells; intrinsic apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Caspase 2 / chemistry
  • Caspase 2 / genetics*
  • Caspase 2 / metabolism*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / metabolism*
  • Cycloheximide / pharmacology
  • Cysteine Endopeptidases / chemistry
  • Cysteine Endopeptidases / genetics*
  • Cysteine Endopeptidases / metabolism*
  • Dactinomycin / pharmacology
  • Doxorubicin / pharmacology
  • Gene Expression Regulation, Neoplastic
  • Gene Knockdown Techniques
  • HEK293 Cells
  • Humans
  • Loss of Function Mutation
  • Protein Stability
  • Sirolimus / pharmacology
  • Transcription Factors / genetics*
  • Transcription Factors / metabolism*
  • Tripartite Motif Proteins / genetics*
  • Tripartite Motif Proteins / metabolism*
  • Ubiquitin-Protein Ligases / genetics*
  • Ubiquitin-Protein Ligases / metabolism*

Substances

  • Antineoplastic Agents
  • Transcription Factors
  • Tripartite Motif Proteins
  • Dactinomycin
  • Doxorubicin
  • Cycloheximide
  • TRIM25 protein, human
  • Ubiquitin-Protein Ligases
  • CASP2 protein, human
  • Caspase 2
  • Cysteine Endopeptidases
  • Sirolimus